Dyne Therapeutics (DYN) AI Stock Analysis

• Market Cap: $928.39M
• Dividend Yield: N/A
• Average Volume (3M): 2.31M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.87
• Revenue Growth: N/A
• EPS Growth: 14.93%
• Country: US
• Employees: 191
• Sector: Healthcare
• Sector Strength: 66
• Industry: Biotechnology
• EPS (TTM): -3.35
• Shares Outstanding: 113,633,780
• 10 Day Avg. Volume: 2,472,918
• 30 Day Avg. Volume: 2,307,141
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -4.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $48.64
• Price Target Upside: 495.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

Dyne Therapeutics' overall score reflects its position as a high-risk, high-reward investment typical of a pre-revenue biotech firm. The company's strong balance sheet and ability to secure funding provide financial stability despite significant operational losses and negative cash flows. The technical indicators suggest a bearish trend, while the valuation highlights the speculative nature of investing in future potential. Recent corporate developments could positively impact future performance, but are not reflected in the current score.

Positive Factors

Regulatory Approval

An accelerated-approval pathway would strengthen DYNE competitiveness in DM1, driving upside.

Valuation

DYN is seen as undervalued, especially given potential approval for DYNE-251 with significant peak sales.

Negative Factors

Potential Safety Risks

Potential safety risks associated with TfR1-targeting include anemia, hemorrhage, and kidney injury.

Regulatory Pathway

The traditional-approval pathway would imply a DYNE-101 approval behind competitor Avidity and can drive downside.

Dyne Therapeutics Business Overview & Revenue Model

Company Description

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

How the Company Makes Money

Dyne Therapeutics generates revenue primarily through strategic collaborations, partnerships, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments for achieving specific clinical or regulatory goals, and royalties on sales of any successfully commercialized products. Additionally, Dyne may receive funding through research grants and government contracts aimed at advancing its therapeutic programs. As the company progresses towards commercialization, potential revenue streams could also include direct sales of approved therapies or sublicensing opportunities with other entities.

Dyne Therapeutics Financial Statement Overview

Summary

Dyne Therapeutics shows typical financial characteristics of a pre-revenue biotech company. The income statement reveals significant losses due to high R&D expenses. However, a strong balance sheet with substantial cash reserves and low debt levels provides financial stability. Despite deeply negative cash flows, the company's ability to raise capital supports ongoing R&D efforts.

Income Statement

Dyne Therapeutics has consistently reported zero revenue over the years, reflecting its early-stage position in the biotechnology sector focused on R&D. The company incurs substantial net losses, which have been increasing over time, indicating high operational expenses without offsetting revenue streams. This results in negative profit margins across all metrics, which is typical for a biotech firm in the pre-commercial phase.

Balance Sheet

The balance sheet is relatively strong with a significant amount of cash and short-term investments, which is crucial for sustaining R&D activities. The company maintains low debt levels relative to its equity, reflected in a healthy debt-to-equity ratio. A robust equity ratio indicates a strong capital structure, providing financial stability and reducing immediate liquidity risks.

Cash Flow

Cash flows are deeply negative, driven by heavy R&D investments, a common scenario for pre-revenue biotech companies. However, the substantial cash on hand and positive financing cash flow from equity funding highlight the company's ability to raise capital, enabling it to continue its development projects despite negative free cash flow growth.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-2.46M	-3.35M	-1.09M	-700.00K
	EBIT
-343.89M	-242.16M	-170.96M	-150.03M	-58.65M
	EBITDA
-343.89M	-233.48M	-164.75M	-148.20M	-58.34M
	Net Income Common Stockholders
-317.42M	-235.94M	-165.24M	-149.28M	-58.74M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
642.27M	123.10M	256.01M	376.57M	345.31M
	Total Assets
691.23M	165.08M	306.32M	425.66M	353.33M
	Total Debt
23.99M	27.41M	30.48M	32.64M	0.00
	Net Debt
-411.46M	-94.21M	-141.66M	-168.19M	-300.85M
	Total Liabilities
61.40M	73.79M	53.96M	57.47M	10.97M
	Stockholders Equity
629.84M	91.29M	252.36M	368.20M	342.37M
Cash Flow		Free Cash Flow
-294.75M	-188.89M	-156.71M	-123.18M	-47.67M
	Operating Cash Flow
-292.37M	-188.16M	-153.65M	-119.56M	-46.51M
	Investing Cash Flow
-204.08M	83.31M	87.20M	-137.89M	-45.66M
	Financing Cash Flow
809.89M	54.32M	37.39M	157.82M	380.69M

Dyne Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Negative. The current price of 8.17 is below the 20-day moving average (MA) of 9.24, below the 50-day MA of 11.61, and below the 200-day MA of 26.84, indicating a bearish trend. The MACD of -1.31 indicates Negative momentum. The RSI at 38.33 is Neutral, neither overbought nor oversold. The STOCH value of 60.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DYN.

Dyne Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WVE	54 Neutral	$908.64M	―	-73.24%	―	-4.42%	-42.17%
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
IOVA	48 Neutral	$1.00B	―	-57.48%	―	13698.99%	31.46%
SNDX	44 Neutral	$992.95M	―	-75.69%	―	―	-25.83%
DYN	39 Underperform	$928.39M	―	-88.03%	―	―	14.93%
VRDN	38 Underperform	$1.07B	―	-45.77%	―	-3.82%	29.10%
ELVN	34 Underperform	$810.04M	―	-32.04%	―	―	12.85%

Dyne Therapeutics Corporate Events

Dyne Therapeutics Appoints Erick Lucera as CFO

On March 20, 2025, Dyne Therapeutics announced the appointment of Erick Lucera as Chief Financial Officer and Treasurer, effective March 31, 2025. This strategic move follows Lucera’s extensive experience in financial leadership roles within the biotechnology sector, notably at Editas Medicine and AVEO Pharmaceuticals. His appointment coincides with the departure of Richard Scalzo, who will transition to a consulting role. These changes are expected to enhance Dyne Therapeutics’ financial strategy and operational efficiency, potentially impacting its market positioning positively.